Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025

Published by KuicK Research Product code 948688
Published Content info 222 Pages
Delivery time: 1-2 business days
Price
Back to Top
Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025
Published: July 13, 2020 Content info: 222 Pages
Description

"Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025" Report Highlights:

  • Bangladesh Pharmaceutical Market Opportunity: More Than US$ 6 Billion by 2025
  • Share Of Local Pharmaceutical Companies: >90%
  • Share of Generics Drugs in Pharmaceutical Market: >75%
  • Leading Drugs Market Insight by Availability, Dosage & Price Analysis
  • Number of Ongoing Clinical Studies: > 300 Clinical Studies
  • Pharmaceutical Exports Opportunity: > US$ 450 Million by 2025

Biotech pioneers of the Bangladesh Pharmaceutical industry are considered as a valuable tool for the overall improvement and efficacy of the market. To a surprise, Bangladesh pharmaceutical market had been largely dependent on the imports as well as on multinational companies for meeting the needs of the local population. However, in recent times local pharmaceutical companies have emerged as the game changer by contributing more than 90% of the overall available medicines in the market. The pharmaceutical market has been witnessing excellent growth in recent years and is expected to surpass US$ 6 Billion by 2025 with absolute growth of 114% from 2019 levels. Majority of this growth will be contributed by local companies with market share of more than 90% as similar to past trends attained over last two decades.

The notable change that attracted the world towards the country's market status is the consequence of innovation in science and research and development sector. This has surprisingly transformed the curve of the overall ratio or contribution of Bangladesh pharmaceutical market at the global level. In a short period of time, the breed of biotechnology firm settled in Bangladesh has accumulated certain practices and has qualified itself to bring down the unmet needs and solutions to numerous patient population. Rise in life expectancy, growing per capita income, changing disease profile, population growth, lifestyle changes and growing patient population are some of the key drivers are that are booming the consumption of local market.

The pioneering impressive export work achieved by the country is the repercussion of the novel biomolecular techniques that have been implemented in the clinical trial platform. The initiatives led by the researchers towards developing a pharmaceutical market have boosted the research and development productivity as well as benefitted the stakeholders and the patients they serve. At present, the total count of the country with respect to clinical trials is more than 300. Bangladesh based pharmaceutical companies have raised their significant amount of clinical trials to advance level. The capital raised by the biotech companies and the research centers has been supported widely by public and private sectors, government bodies and the regulatory bodies.

Being abundant in pharmaceutical based human resources is formulating the market towards several development programs. Although the country has been competing powerfully with the other emerged markets of the world but digital stringency, which been a transforming source for the other markets is on the move in Bangladesh at a very slow pace. It is important for the Bangladesh pharmaceutical market to interact with dominating markets to improve their platforms for drug discovery and development sector in order to strike with pharmaceutical market of the US and Europe.

In upcoming years, the government of Bangladesh will play a major role in the rapid growth of pharmaceutical market by providing favorable policies for easy drug approval, production and marketing of new products. Government is focusing to reduce the dependence of Bangladesh over import of raw material and establishment of API Park will act as turning point for this purpose. The top 50 companies are setting their facilities at the active pharmaceuticals ingredient industrial park that will help in production of patented and already opened active pharmaceuticals ingredients. It is expected that the development of API Park will complete by next 2 years, which will reduce the expenditure related to import of raw material.

All the associated factors are in favor for the rapid growth Bangladesh pharmaceutical market and it is expected to grow with a CAGR of more than 12% during 2019-2025 period. The share of generic drugs is expected to surpass 85% by the 2025, which will further strengthen the dominance of local pharmaceutical companies in the market. In addition to this, the presence of leading multinational pharmaceutical companies is also increasing in Bangladesh, which is indicating towards the competitive landscape in upcoming years.

Table of Contents

Table of Contents

1. Introduction to Bangladesh Pharmaceutical Market

  • 1.1. Overview
  • 1.2. Current Market Scenario

2. Bangladesh - Cancer Prevalence & Statistics

  • 2.1. Overview
  • 2.2. By Gender
  • 2.3. By Age
  • 2.4. By Leading Cancer Type
    • 2.4.1. Oesophagus Cancer
    • 2.4.2. Lip,Oral Cavity Cancer
    • 2.4.3. Breast Cancer
    • 2.4.4. Lung Cancer
    • 2.4.5. Cervix Uteri Cancer

3. Bangladesh - Diabetes Prevalence & Statistics

  • 3.1. By Population
  • 3.2. By Diabetes Type
    • 3.2.1. Type 1 Diabetes
    • 3.2.2. Type 2 Diabetes
  • 3.3. By Age & Gender
  • 3.4. Obesity & Overweight

4. Bangladesh HIV Infection - Prevalence & Statistics

5. Bacterial & Viral Infections in Bangladesh - Prevalence& Statistics

  • 5.1. Hepatitis-B
  • 5.2. Diarrheal Disease
  • 5.3. Tuberculosis
  • 5.4. Pneumonia & Influenza

6. Cardiovascular Diseases in Bangladesh - Prevalence & Statistics

  • 6.1. Hypertension
  • 6.2. Coronary Heart Disease & Stroke

7. Bangladesh Pharmaceutical Market Segmentation

  • 7.1. By Product - Generics & Patented Drugs
  • 7.2. By Treatment System
  • 7.3. By Local & Multinational Companies
  • 7.4. By Therapeutic Class
  • 7.5. By Trade - Import & Export Market

8. Bangladesh Pharmaceutical Market Leading Drugs Insight - Availability, Dosage & Price Analysis

  • 8.1. Seclo (Omeprazole)
  • 8.2. Sergel (Esomeprazole)
  • 8.3. Maxpro (Esomeprazole)
  • 8.4. Pantonix (Pantoprazole)
  • 8.5. CEF-3(Cefixime Trihydrate)
  • 8.6. Mixtard 30(Insulin Human & Isophane Insulin Human)
  • 8.7. Napa Extra (Paracetamol & Caffeine)
  • 8.8. Losectil (Omeprazole)
  • 8.9. Napa (Paracetamol)
  • 8.10. Exium (Esomeprazole)

9. Bangladesh Pharmaceutical Market - Clinical Trials Insight

  • 9.1. By Phase
  • 9.2. By Recruiting Status
  • 9.3. By Indication

10. Bangladesh Pharmaceutical Market Dynamics

  • 10.1. Drivers for Bangladesh Pharmaceutical Market
  • 10.2. Challenges for Bangladesh Pharmaceutical Market

11. Bangladesh Pharmaceutical Market Future Outlook

12. Competitive Landscape

  • 12.1. Local Companies
    • 12.1.1. Square Pharmaceuticals
    • 12.1.2. Incepta Pharma
    • 12.1.3. Beximco Pharma
    • 12.1.4. Opsonin Pharma
    • 12.1.5. Ranata Limited
    • 12.1.6. Beacon Pharmaceuticals
    • 12.1.7. Chemist Laboratories
    • 12.1.8. Central Pharmaceuticals
    • 12.1.9. Delta Pharma
    • 12.1.10. Everest Pharmaceuticals
    • 12.1.11. Desh pharmaceuticals
    • 12.1.12. Decent Pharmaceuticals
    • 12.1.13. FNF Pharmaceuticals
  • 12.2. Multinational Companies
    • 12.2.1. Amgen
    • 12.2.2. Eli - Lilly
    • 12.2.3. Merck
    • 12.2.4. Pfizer
    • 12.2.5. GlaxoSmithKline
    • 12.2.6. Roche
    • 12.2.7. AstraZeneca
    • 12.2.8. Genentech
    • 12.2.9. Sanofi
    • 12.2.10. Novo Nordisk

List of Figures

  • Figure 1-1: Bangladesh - Per Capita Healthcare Expenditure (US$), 2015 - 2017
  • Figure 1-2: Bangladesh - Healthcare Expenditure (US$ Billion), 2015 - 2017
  • Figure 1-3: Bangladesh - Pharmaceutical Market Share by Local v/s Multinational Companies (BDT/US$ Billion), 2018
  • Figure 1-4: Bangladesh - Pharmaceutical Market Size (BDT/US$ Billion), 2015 - 2019
  • Figure 1-5: Bangladesh - Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
  • Figure 1-6: Bangladesh - Production Share of Generics & Patented Drugs (%), 2018
  • Figure 1-7: Bangladesh - Pharmaceutical Export Market (US$ Million), 2015 - 2019
  • Figure 2-1: Bangladesh - Newly Diagnosed Cancer Cases, 2018, 2020 & 2025
  • Figure 2-2: Bangladesh - Number of Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-3: Bangladesh - Newly Diagnosed Cancer Cases by Leading Cancer Type, 2018
  • Figure 2-4: Bangladesh - Newly Diagnosed Cancer Cases by Leading Cancer Type (%), 2018
  • Figure 2-5: Bangladesh - Cancer Related Deaths by Leading Cancer Type, 2018
  • Figure 2-6: Bangladesh - Cancer Related Deaths by Leading Cancer Type (%), 2018
  • Figure 2-7: Bangladesh - Newly Diagnosed Cancer Cases by Gender, 2018
  • Figure 2-8: Bangladesh - Cancer Related Deaths by Gender, 2018
  • Figure 2-9: Bangladesh - Newly Diagnosed Cancer Cases by Gender (%), 2018
  • Figure 2-10: Bangladesh - Newly Diagnosed Male Cancer Cases, 2018, 2020 & 2025
  • Figure 2-11: Bangladesh - Newly Diagnosed Female Cancer Cases, 2018, 2020 & 2025
  • Figure 2-12: Bangladesh - Male Cancer Cases by Cancer Type, 2018
  • Figure 2-13: Bangladesh - Female Cancer Cases by Cancer Type (%), 2018
  • Figure 2-14: Bangladesh - Age Standardized Incidence Rate of Leading Male Cancer (Per 100'000 People), 2018
  • Figure 2-15: Bangladesh - Age Standardized Incidence Rate of Leading Female Cancer (Per 100'000 People), 2018
  • Figure 2-16: Bangladesh - Newly Diagnosed Cancer Cases by Age, 2018
  • Figure 2-17: Bangladesh - Newly Diagnosed Cancer Cases by Age (%), 2018
  • Figure 2-18: Bangladesh - Cancer Related Deaths by Age, 2018
  • Figure 2-19: Bangladesh - Newly Diagnosed Cancer Cases by Age (%), 2018
  • Figure 2-20: Bangladesh - Oesophagus Cancer Cases, 2018, 2020 & 2025
  • Figure 2-21: Bangladesh - Oesophagus Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-22: Bangladesh - Age-Standardized Oesophagus Cancer Incidence & Mortality Rate (Per 100'000 People), 2018
  • Figure 2-23: Bangladesh - Lip,Oral Cavity Cancer Cases, 2018, 2020 & 2025
  • Figure 2-24: Bangladesh - Lip, Oral Cavity Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-25: Bangladesh - Age-Standardized Lip, Oral Cavity Cancer Incidence & Mortality Rate (Per 100'000 People), 2018
  • Figure 2-26: Bangladesh - Breast Cancer Cases, 2018, 2020 & 2025
  • Figure 2-27: Bangladesh - Breast Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-28: Bangladesh - Age-Standardized Breast Cancer Incidence & Mortality Rate (Per 100'000 People), 2018
  • Figure 2-29: Bangladesh - Lung Cancer Cases, 2018, 2020 & 2025
  • Figure 2-30: Bangladesh - Lung Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-31: Bangladesh - Age-Standardized Lung Cancer Incidence & Mortality Rate (Per 100'000 People), 2018
  • Figure 2-32: Bangladesh - Cervix Uteri Cancer Cases, 2018, 2020 & 2025
  • Figure 2-33: Bangladesh - Cervix Uteri Cancer Related Deaths, 2018, 2020 & 2025
  • Figure 2-34: Bangladesh - Age-Standardized Cervix Uteri Cancer Incidence & Mortality Rate (Per 100'000 People), 2018
  • Figure 3-1: Bangladesh - Adult Diabetic Population (Million), 2010 & 2019
  • Figure 3-2: Bangladesh - Estimated Number of Adult Diabetic Population (Million), 2030 & 2045
  • Figure 3-3: Bangladesh - Diagnosed v/s Undiagnosed Adult Diabetic Population (Million), 2019
  • Figure 3-4: Bangladesh - Diagnosed v/s Undiagnosed Adult Diabetic Population Share (%), 2019
  • Figure 3-5: Bangladesh - Age Adjusted Diabetes Prevalence Rate (%), 2019, 2030 & 2045
  • Figure 3-6: Bangladesh - Diabetes Related Deaths, 2010 & 2019
  • Figure 3-7: Bangladesh - Population Estimates (Million), 2019, 2020, 2025 & 2030
  • Figure 3-8: Bangladesh - Adult Diabetes Cases by Type (Million), 2019
  • Figure 3-9: Bangladesh - Diabetes Cases by Type (%), 2019
  • Figure 3-10: Bangladesh - Type 1 Diabetic Adult Population (Million), 2019, 2025 & 2045
  • Figure 3-11: Bangladesh - Total & Newly Diagnosed Type 1 Diabetic Cases in Age below 19 Years, 2019
  • Figure 3-12: Bangladesh - Type 2 Diabetic Population (Million), 2019, 2030 & 2045
  • Figure 3-13: Bangladesh - Diabetes Prevalence Rate by Gender (%), 2016
  • Figure 3-14: Bangladesh - Newly Diagnosed Type 1 Diabetes Cases in Children by Age, 2019
  • Figure 3-15: Bangladesh - Type 1 Diabetes Cases in Children by Age, 2019
  • Figure 3-16: Bangladesh - Type 1 Diabetes Cases in Children by Age (%), 2019
  • Figure 3-17: Bangladesh - Obesity Prevalence Rate by Gender (%), 2019
  • Figure 3-18: Bangladesh - Obese Population v/s Total Population (Million), 2020
  • Figure 4-1: Bangladesh - Total HIV Cases & Newly Diagnosed HIV Cases, 2018
  • Figure 4-2: Bangladesh - HIV Cases, 2010, 2015 & 2018
  • Figure 4-3: Bangladesh - New Diagnosed HIV Cases, 2010, 2015 & 2018
  • Figure 4-4: Bangladesh - New Diagnosed HIV Cases by Gender, 2018
  • Figure 4-5: Bangladesh - New Diagnosed HIV Cases by Gender (%), 2018
  • Figure 4-6: Bangladesh - Total HIV Cases by Age & Gender, 2018
  • Figure 4-7: Bangladesh - Number of HIV Patients by Known Status & ART Therapy, 2018
  • Figure 4-8: Bangladesh - Number of HIV Patients by Known Status & ART Therapy (%), 2018
  • Figure 4-9: Bangladesh - Share of ART Receiving Patients In Total HIV Patients (%), 2015 - 2018
  • Figure 4-10: Bangladesh - Number of ART Receiving Patients by Gender, 2018
  • Figure 4-11: Bangladesh - Number of ART Receiving Patients by Gender (%), 2018
  • Figure 4-12: Bangladesh - ART Receiving Patients by Age, 2018
  • Figure 4-13: Bangladesh - Patients with Late HIV Diagnosis by CD4 Cell Count (%), 2018
  • Figure 5-1: Bangladesh - Known & Unknown Hepatitis-B Infection Cases (%), 2018
  • Figure 5-2: Bangladesh - Risk of Developing other Liver Complication due to Hepatitis-B (%), 2018
  • Figure 5-3: Bangladesh - Number of Children Born with Hepatitis-B Infection (%), 2018
  • Figure 5-4: Bangladesh - Number of Diarrhea Related Deaths (Per 1 Million People), 2003, 2013 & 2018
  • Figure 5-5: Bangladesh - Diarrhea Cases by Causative Microorganism, 2018
  • Figure 5-6: Bangladesh - Diarrhea Related Deaths v/s Others, 2018
  • Figure 5-7: Bangladesh - New/Relapsed Tuberculosis Cases & Deaths by Type, 2018
  • Figure 5-8: Bangladesh - Estimated Tuberculosis Incidence Rate by Type, 2018
  • Figure 5-9: Bangladesh - New & Relapsed TB Cases v/s Number of Estimated TB Cases, 2018
  • Figure 5-10: Bangladesh - New & Relapsed TB Cases by Gender & Age, 2018
  • Figure 5-11: Bangladesh - Adult TB Cases by Gender, 2018
  • Figure 5-12: Bangladesh - Pneumonia Related Deaths in Age less than 5 Years, 2018
  • Figure 5-13: Bangladesh - Pneumonia Related Deaths in Age less than 5 Years (%), 2018
  • Figure 6-1: Bangladesh - Total Population v/s Population with Hypertension (Million), 2020
  • Figure 6-2: Bangladesh - Share of Hypertensive Patient (%), 2020
  • Figure 6-3: Bangladesh - Hypertensive Population by Status (Million), 2020
  • Figure 6-4: Bangladesh - Hypertensive Population by Status (Million), 2020
  • Figure 6-5: Bangladesh - Hypertensive Prevalence in Urban & Rural Area (%), 2017
  • Figure 6-6: Bangladesh - Hypertensive Prevalence by Gender (%), 2017
  • Figure 6-7: Bangladesh - Hypertensive Prevalence by Age (%), 2017
  • Figure 6-8: Bangladesh - Number of Coronary Heart Disease & Stroke Related Deaths, 2018
  • Figure 6-9: Bangladesh -Coronary Heart Disease & Stroke Related Deaths v/s Deaths Related to Other Complications, 2018
  • Figure 6-10: Bangladesh - Age adjusted Death Rate of Coronary Heart Disease & Stroke (Per 100'000), 2018
  • Figure 7-1: Bangladesh - Generic Pharmaceutical Market Size (BDT/US$ Billion), 2016 - 2019
  • Figure 7-2: Bangladesh - Generic Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
  • Figure 7-3: Bangladesh - Top 10 Generic Pharmaceutical Company by Market Share (%), 2017
  • Figure 7-4: Bangladesh - Top 10 Generic Pharmaceutical Company by Market Share (%), 2017
  • Figure 7-5: Bangladesh - Patented Pharmaceutical Market Size (BDT/US$ Billion), 2020 - 2025
  • Figure 7-6: Bangladesh - Number of Registered Allopathic Manufacturers, Drugs, Generics & Retail Pharmacies, 2018
  • Figure 7-7: Bangladesh - Number of Registered Homeopathic Manufacturers, Drugs & Retail Pharmacies, 2018
  • Figure 7-8: Bangladesh - Number of Registered Unani Manufacturers, Drugs & Retail Pharmacies, 2018
  • Figure 7-9: Bangladesh - Number of Registered Ayurvedic Manufacturers, Drugs & Retail Pharmacies, 2018
  • Figure 7-10: Bangladesh - Local Pharmaceutical Market Size (BDT/US$ Billion), 2015 - 2018
  • Figure 7-11: Bangladesh - Pharmaceutical Market Size of Multinational Companies (BDT/US$ Billion), 2015 - 2018
  • Figure 7-12: Bangladesh - Pharmaceutical Market Size by Type of Companies (BDT/US$ Billion), 2025
  • Figure 7-13: Bangladesh - Share of Leading Local Pharma Company in Total Pharmaceutical Market (%), Q2 2017
  • Figure 7-14: Bangladesh - Share of Leading MNCs Pharma Company in Total Pharmaceutical Market (%), Q2 2017
  • Figure 7-15: Bangladesh - Pharmaceutical Market Size by Therapeutic Class (BDT/US$ Billion), 2018
  • Figure 7-16: Bangladesh - Year over Year Growth Rate by Therapeutic Segment (%), 2018
  • Figure 7-17: Bangladesh - Share of Gastroenterological Class in Total Pharma Market (%), 2015 - 2018
  • Figure 7-18: Bangladesh - Share of Anti-Infectives in Total Pharma Market (%), 2015 - 2018
  • Figure 7-19: Bangladesh - Share of Pain Killers in Total Pharma Market (%), 2015 - 2018
  • Figure 7-20: Bangladesh - Pharmaceutical Export Market (US$ Million), 2019 - 2025
  • Figure 7-21: Bangladesh - Pharmaceutical Export & Import Market (US$ Million), 2019
  • Figure 7-22: Bangladesh - Share of Imported API in Total API Consumption (%), 2019
  • Figure 7-23: Bangladesh - Pharmaceutical Export Earnings by Countries (US$ Million), 9 Month'2019
  • Figure 7-24: Bangladesh - Bxpharma Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
  • Figure 7-25: Bangladesh - Square Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
  • Figure 7-26: Bangladesh - Ranata Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
  • Figure 7-27: Bangladesh - ACME Pharmaceutical Export Earnings (BDT/US$ Million), 2016 - 2018
  • Figure 8-1: Seclo - Price for 120 Capsules, 5 Capsules & Price per Unit capsule of 20mg (BDT/US$), July'2020
  • Figure 8-2: Seclo - Price for 120 Capsules, 5 Capsules & Price per Unit capsule of 40mg (BDT/US$), July'2020
  • Figure 8-3: Seclo - Recommended Oral Dose by Indication (mg/day), July'2020
  • Figure 8-4: Seclo - Recommended IV Dose by Indication (mg/day), July'2020
  • Figure 8-5: Sergel - Price for 100 Capsules & Price per Unit Capsule of 20mg (BDT/US$), July'2020
  • Figure 8-6: Sergel - Price for 50 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July'2020
  • Figure 8-7: Sergel - Price for 30 Tablets & Price per Unit Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-8: Seclo - Price for 30 Tablets & Price per Unit Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-9: Sergel - Recommended Adult & Pediatric Dose (mg/day)
  • Figure 8-10: Maxpro - Price for 140 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-11: Maxpro - Price for 5 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-12: Maxpro - Price for 40 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-13: Maxpro - Price for 10 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-14: Maxpro - Price for 100 Capsules, 14 Capsules & Price per Unit Capsule of 20mg (BDT/US$), July'2020
  • Figure 8-15: Maxpro - Price for 60 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July'2020
  • Figure 8-16: Sergel - Recommended Adult & Pediatric Dose (mg/day)
  • Figure 8-17: Pantonix - Price for 70 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-18: Pantonix - Price for 14 Tablet & Price per Unit Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-19: Pantonix - Price for 70 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-20: Pantonix - Price for 14 Tablet & Price per Unit Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-21: Pantonix - Recommended Minimum & Maximum Oral Dose (mg/day)
  • Figure 8-22: Pantonix - Minimum & Maximum Duration of Oral Therapy (Weeks)
  • Figure 8-23: Pantonix - Recommended Minimum & Maximum Intravenous Dose (mg/day)
  • Figure 8-24: Cef-3 - Price for 14 Capsule & Price per Unit Capsule of 200mg (BDT/US$), July'2020
  • Figure 8-25: Cef-3 - Price for 6 Capsules, 12 Capsules & Price per Unit Capsule of 400mg (BDT/US$), July'2020
  • Figure 8-26: Cef-3 Suspension - Price for 30ml, 50ml & 75ml Suspension of Dose 100mg/5ml (BDT/US$), July'2020
  • Figure 8-27: Cef-3 Suspension - Price for 50ml Supply & Price per ml of 200mg/5ml Suspension (BDT/US$), July'2020
  • Figure 8-28: Cef-3 Pediatric Drops - Price for 21ml Supply & Price per ml of 25mg/ml Drops (BDT/US$), July'2020
  • Figure 8-29: Cef-3 - Recommended Minimum & Maximum Dose for Gonorrhea (mg/day)
  • Figure 8-30: Cef-3 - Usual Adult & Pediatric Dose (mg/day)
  • Figure 8-31: Mixtard 30 - Price for 10ml & Price per ml of 40IU/ml Vial (BDT/US$), July'2020
  • Figure 8-32: Mixtard 30 - Price for 10ml & Price per ml of 100 IU/ml Vial (BDT/US$), July'2020
  • Figure 8-33: Mixtard 30 - Price for 5 Penfill Supply & Price for Single Penfill of 100 IU/ml Vial (BDT/US$), July'2020
  • Figure 8-34: Mixtard 30 - Price for 5 Flexpen Supply & Price for Single Flexpen of 100 IU/ml Vial (BDT/US$), July'2020
  • Figure 8-35: Mixtard 30 - Recommended Minimum & Maximum Dose for Type 1 Diabetes (IU/Kg/Day), July'2020
  • Figure 8-36: Mixtard 30 - Recommended Minimum & Maximum Dose for Type 2 Diabetes (IU/Kg/Day), July'2020
  • Figure 8-37: Napa Extra - Price for 240 Tablets & Price per Unit Tablet (BDT/US$), July'2020
  • Figure 8-38: Napa Extra - Price for 12 Tablets & Price per Unit Tablet (BDT/US$), July'2020
  • Figure 8-39: Napa Extra - Minimum & Maximum Cost of Daily Treatment (BDT/US$), July'2020
  • Figure 8-40: Losectill - Price for 40 Capsules & Price per Unit Capsule of 10mg (BDT/US$), July'2020
  • Figure 8-41: Losectill - Price for 100, 120 & 500 Capsules of 20mg (BDT/US$), July'2020
  • Figure 8-42: Losectill - Price for 60 Capsules & Price per Unit Capsule of 40mg (BDT/US$), July'2020
  • Figure 8-43: Losectill - Price for 50 Sachets & Price for Single Sachet of 20mg (BDT/US$), July'2020
  • Figure 8-44: Losectill - Price for 30 Sachets & Price for Single Sachet of 20mg (BDT/US$), July'2020
  • Figure 8-45: Losectil - Recommended Minimum & Maximum Oral Dose (mg/day), July'2020
  • Figure 8-46: Losectil - Recommended Minimum & Maximum IV Dose (mg/day), July'2020
  • Figure 8-47: Napa - Price for 500 Tablet Supply & 10 Tablet Supply of 500mg (BDT/US$), July'2020
  • Figure 8-48: Napa - Price for 200 Tablet Supply & Price per unit Tablet of 1000mg (BDT/US$), July'2020
  • Figure 8-49: Napa Suspension - Price for 50ml Supply & 60ml Supply of 120mg/5ml Suspension (BDT/US$), July'2020
  • Figure 8-50: Napa Syrup - Price for 50ml, 60ml & 100ml Supply of 120mg/5ml Syrup (BDT/US$), July'2020
  • Figure 8-51: Napa Pediatric Drops - Price for 15ml Supply & Price per unit ml of 80mg/ml Drops (BDT/US$), July'2020
  • Figure 8-52: Napa Suppositories - Price for 20 Suppositories of various Dose Regimen (BDT/US$), July'2020
  • Figure 8-53: Napa IV Solution - Price for 100ml Supply & Price per unit ml of Intravenous Solution (BDT/US$), July'2020
  • Figure 8-54: Napa Tablet - Minimum & Maximum Recommended Adult Dose (gm/day), July'2020
  • Figure 8-55: Napa Tablet - Pediatric Dose by Age (mg/ 4 Times a day), July'2020
  • Figure 8-56: Exium - Price for 100 Capsules Supply & Price per unit Capsule of 20mg (BDT/US$), July'2020
  • Figure 8-57: Exium - Price for 60 Capsules Supply & Price per unit Capsule of 40mg (BDT/US$), July'2020
  • Figure 8-58: Exium - Price for 56 Tablets Supply & Price per unit MUPS Tablet of 20mg (BDT/US$), July'2020
  • Figure 8-59: Exium - Price for 28 Tablets Supply & Price per unit MUPS Tablet of 40mg (BDT/US$), July'2020
  • Figure 8-60: Exium - Minimum & Maximum Recommended Adult Dose (mg/day), July'2020
  • Figure 8-61: Exium - Minimum & Maximum Recommended Pediatric Dose (mg/day), July'2020
  • Figure 9-1: Bangladesh - Number of Clinical Trials by Phase, June'2020
  • Figure 9-2: Bangladesh - Clinical Trials by Phase (%), June'2020
  • Figure 9-3: Bangladesh - Number of Clinical Trials by Status, June'2020
  • Figure 9-4: Bangladesh - Clinical Trials by Status (%), June'2020
  • Figure 9-5: Bangladesh - Number of Clinical Trials by Infectious & Non Infectious Diseases (%), June'2020
  • Figure 9-6: Bangladesh - Number of Clinical Trials by Indications, June'2020
  • Figure 9-7: Bangladesh - Clinical Trials by Indication (%), June'2020
  • Figure 10-1: Bangladesh Pharmaceutical Market Drivers
  • Figure 10-2: Challenges for Bangladesh Pharmaceutical Market
Back to Top